IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In re application of: Heinrich et al.

Application No. 10/517,905 Filed: December 10, 2004

FILED VIA EFS

Confirmation No. 4619

FOI: ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS

Examiner: Zachary C. Howard

Art Unit: 1646

Attornev Reference No. 899-65892-02

FILED VIA ELECTRONIC FILING SYSTEM COMMISSIONER FOR PATENTS

TRANSMITTAL LETTER

Submitted herewith is an Amendment (accompanied by Exhibits A-G) for the above application. The fee has been calculated as shown:

CLAIMS AS AMENDED						
For	No. after amendment	No. paid for previously		Present Extra	Rate	Fee
Total Claims	44	- 60*	=	0	\$26.00	\$ 0.00
Indep. Claims	1	- 3**	=	0	\$110.00	\$ 0.00
Three-month Extension of Time \$555.00						\$555.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT						\$555.00

Applicants petition for a three-month extension of time and submit the required fee of \$555.00 herewith via EFS. The Director is hereby authorized to charge any additional fees that may be required in connection with the filing of this Amendment, or credit over-payment, to Account No. 02-4550.

Respectfully submitted,

KLAROUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301 By /Tanya M. Harding/

Tanya M. Harding, Ph.D. Registration No. 42,630